BackImmuneering Overview
Immuneering Corp - Ordinary Shares Class A

Immuneering Target Price

See Immuneering's analyst price targets ($13) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.68

Average Target Price

$12.50239.7% upside

2 analysts in the last 4 months

High: $14 | Low: $11

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-29Mizuho Securities$11198.9% upsideOpen
2026-08-06UBS$14280.4% upsideOpen
2026-07-08Cantor FitzgeraldLi Watsek$17362% upsideOpen
2026-03-09Piper Sandler$12226.1% upsideOpen
2025-10-29Mizuho Securities$12226.1% upsideOpen
2025-09-25OppenheimerJay Olson$30715.2% upsideOpen
2024-04-02Mizuho SecuritiesGraig Suvannavejh$8117.4% upsideOpen
2024-03-15JefferiesMichael Yee$318.5% downsideOpen
2022-09-30Piper SandlerSwapnil Malekar$411014.1% upsideOpen
2022-07-09Loop Capital MarketsGeulah Livshits$18389.1% upsideOpen

Immuneering (IMRX) FAQ

Immuneering (IMRX) currently reports a target price of $13. Use the charts on this page to explore Immuneering's target price history and peer comparisons.

Analysts' average 12-month price target for Immuneering is $13, about 239.7% upside from the current share price of $3.68. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $13, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Immuneering, and consider following IMRX for alerts when major investors trade the stock.

Immuneering is classified in the Healthcare sector. On target price, it currently shows $13. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMRX with unrelated industries.